PDF - 2 Mo

!"#$"%&'(%)*+,&-"&.&/(01"+2&"+)&3$/'+(%(,2&(!$4!*$5&.&(/3(6$4&7899&
&&
:;<=>&789?&
www.vaxeal(group.com0
/@ABCD=&E&3FGHD@<@I=&(JFKJLFM&

!"#$"%&.&/(01"+2&"+)&3$/'+(%(,2&(!$4!*$5&
! -0$&N@;DOFO&LD&788P&Q&'FCOR;CKSFKFO&LD&!FJF=&T/'U&V&"W<LCSFX&LD&YKCDGF&T4E)U&CDO&/HLDC&&
! )FJF<@BAFDS&@N&D@JF<&IFDFKCZ@D&@N&Long0Synthe7c0Pep7de(based0therapeu7c0vaccines0LD&
G@A[LDCZ@D&MLSH&immunomodulatory0drugs0
! Y@G;X&@D&<CKIF&ACK\FS&@BB@KS;DLZFX&MLSH&MAJOR&I<@[C<&BCZFDS&;DAFS&AFOLGC<&DFFOX]&&
9U &Cancer]&-;KJLJLD>&0LO\LDF&CDO&/6#Q9&
7U &Infec)ous-diseases:0'FBCZZX&/&IFD@S=BF&9&^&_&
! Strong0IP0Posi7on0]&`&<LGFDXFO&BCSFDSX&V&7&BFDOLDI&BCSFDSX&
! Seed0Investment:0?&AL<<L@D&a&V&Y@;DOFKX&A@DF=&V&9b&=FCKX&CGCOFALG&LDJFXSAFDS&
! Strategic0Academic0Partners0
OVERVIEW0
7&

!"#$"%&.&/(01"+2&"+)&3$/'+(%(,2&(!$4!*$5&
Dr0Ahmed0Bouzidi,0PhD,0MBA0–0CEO0
Q -;GGFXXN;<&FDSKFBKFDF;K&LD&$;K@BF&CDO&/HLDC&&
Q 6@CKO&AFA[FK&@N&$6$Q6L@BHCKAC&
Q 0FA[FK&@N&SHF&4E)&3CX\&Y@KGF&@N&!CGGLDFX&$;K@BF&
Mr0Serge0Grisard,0Msc,0MBA,0EVP0Corporate0
Development0
Q 9c&=FCKX&FdBFKLFDGF&LD&'FC<SHGCKF&BK@O;GS&
OFJF<@BAFDS>&/@AAFKGLC<LeCZ@D&CDO&111X&
Q ,<@[C<&ACDCIFAFDS&CS&-LFAFDX&0FOLGC<>&1feFK>&
"XSKCQgFDFGC>&CDO&C&KCDIF&@N&BKLJCSF&XSCKSQ;BX0
Pr0Giampietro0Corradin,0PhD0–0CTO0
Q 5@K<OMLOF&FdBFKS&LD&%-1Q[CXFO&JCGGLDFX&T?8&=FCKX&
FdBFKLFDGFU&
Q )FJF<@BAFDS&@N&XFJFKC<&JCGGLDF&GCDOLOCSFX&
Dr0Jérôme0Kerzerho,0PhD0–0Director0R&D0
Q $dBFKS&LD&LAA;D@<@I=&
Q )LXG@JFKFO&SHF&S;A@K&CDZIFDX&0LO\LDF&
Q *OFDZfFO& DFM& G<LDLGC<<=& KF<FJCDS& 3& GF<<& FBLS@BFX& LD&
-;KJLJLD&CDO&0LO\LDF&S;A@K&CDZIFDX0
EXECUTIVE0TEAM0
?&
SCIENTIFIC0ASSOCIATES0
Pr0Eric0Tartour,0MD,0PhD0–0Immuno(Oncology0
Q )LKFGS@K&@N&SHF&GCDGFK&LAA;D@A@DLS@KLDI&
OFBCKSAFDS&@N&'$,1&T1CKLXU&
Q )LKFGS@K&@N&CD&*DXFKA&SFCA&OFOLGCSFO&S@&GCDGFK&
LAA;D@SHFKCB=&
Q /<LDLGC<&OFJF<@BAFDS&@N&XFJFKC<&GCDGFK&
LAA;D@SHFKCBLFX0
Pr0Pedro0Romero,0MD,0PhD0–0Immuno(Oncology0
Q 5@KO<MLOF&(DG@<@I=&FdBFKS&CS&%;OMLI&LDXZS;SF&
Q $<;GLOCZ@D&@N&SHF&LAA;D@<@ILGC<&AFGHCDLXAX&@N&
GCDGFK&SHFKCBF;ZG&JCGGLDFX&
Q %C;KFCSF&@N&SHF&4@[FKSQ5FDDFK&CMCKO&LD&7889&T[FXS&
-MLXX&KFXFCKGHFKU0
Dr0Bernard0Maillère,0PhD,0Eng.0–0Immunology0
Q )LKFGS@K&@N&SHF&OFBCKSAFDS&@N&LAA;D@GHFALXSK=&@N&
GF<<;<CK&LAA;DF&KFXB@DXF&CS&SHF&/$"&TY4U&
Q )FJF<@BFO&SHF&1KFOLGZJF&B<Ch@KA&@N&!CdFC<0
Pr0François0Sper7ni,0MD,0PhD0–0Virology0
Q $dBFKS&LD&JCGGLDF&G<LDLGC<&OFJF<@BAFDS&
Q Y@G;XFO&@D&SHF&OFJF<@BAFDS&@N&D@JF<&JCGGLDF&
XSKCSFILFX&LD&SHF&fF<O&@N&HFBCZZX&/>&S;[FKG;<@XLX>&
0C<CKLC&CDO&C<<FKI=0

!"#$"%&.&/(01"+2&"+)&3$/'+(%(,2&(!$4!*$5&
ADVANCED0PROPRIETARY0TECHNOLOGY0PLATFORMS0FOR…0
IMMUNOGENICITY+
PREDICTION++
&!
T+CELL+EPITOPE+
IDENTIFICATION&
PRODUCTION+/
FORMULATION/
COMBINATIONS&
PRE6CLINICAL+
VALIDATION&
IMMUNO6MONITORING+
OF+CLINICAL+TRIALS&
" "&KCBLO&LOFDZfGCZ@D&@N&KF<FJCDS&3&GF<<&FBLS@BFX&S@&[F&
LDG@KB@KCSFO&LD&C&JCGGLDF!
" 3HF&OFXLID>&N@KA;<CZ@D&CDO&JC<LOCZ@D&@N&SHF&JCGGLDF&
GCDOLOCSFX!
" 1KFQG<LDLGC<&BK@@N&@N&G@DGFBS&XS;OLFX&
" 3HF& FJC<;CZ@D& @N& X=DFKILXZG& G@A[LDCZ@D& @N& SHF&
N@KA;<CSFO&JCGGLDFX&MLSH&LAA;D@A@O;<CS@K=&CIFDSX!
" 3HF&LAA;D@A@DLS@KLDI&@N&G<LDLGC<&SKLC<X!

!"#$"%&.&/(01"+2&"+)&3$/'+(%(,2&(!$4!*$5&
VAXEAL0(0PIPELINE0
b&
!"#$%&'(
)*$)&+')#*(
,-+$(
#!').)/+')#*(
!"-0&,)*)&+,(
!010&(
!2+3-()(
4)5))6(
!+"'*-"3(
.+"7-'(
!#'-*')+,(
(
(
!
389:;:;<((
43=>0?6!(1)(
!91@ABACD("C<BE(B<F(
!B<G9CB@(GB<GC9@D(
.CAB@ABA;G(HCEB<1HB(
!
I?(JK?L!
)*3-".(
0(
,8FM;N!
!
O(PQR<5(SCB9!
.;FT;<C((
4.$>0?6!(2)(
*3&,&D(&1E19CGABED(U9CB@A(
B<F(#:B9;B<(GB<GC9@(
!!
!!
IV(JK?L(
O(PQR<5(SCB9!
&U>0?((3)(
.8EA;WEC(&B<GC9@(
!!
!!
I?(JK?Q(
O(PQR<5(SCB9!
&1HR1((1+2+3)(
.8EA;WEC(&B<GC9@(
!!
!!
IV(JK?X(
O(PQR<5(SCB9!
(
(
!
!
!
!
!
!
!
&19C5*3V(
2CWBA;A;@(&(NC<Y?5X((
!
I?(JK?L!
&.&!
O(PQR<5(SCB9!
!